{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:48:32Z","timestamp":1791082112415,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1124\/jpet.105.085597","type":"journal-article","created":{"date-parts":[[2005,9,19]],"date-time":"2005-09-19T14:28:09Z","timestamp":1127140089000},"page":"58-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"title":["Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor \u03b3 Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis"],"prefix":"10.1016","volume":"315","author":[{"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Renga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mencarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pruzanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pellicciari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.085597_bib1","doi-asserted-by":"crossref","unstructured":"Bedoucha M, Atzpodien E, and Boelsterli UA (2001) Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35: 17-23.","DOI":"10.1016\/S0168-8278(01)00066-6"},{"key":"10.1124\/jpet.105.085597_bib2","doi-asserted-by":"crossref","unstructured":"Berger J and Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435.","DOI":"10.1146\/annurev.med.53.082901.104018"},{"key":"10.1124\/jpet.105.085597_bib3","doi-asserted-by":"crossref","unstructured":"Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, Caliendo G, Santagada V, Morelli A, and Cirino G (2004a) PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 39:365-375.","DOI":"10.1002\/hep.20054"},{"key":"10.1124\/jpet.105.085597_bib4","doi-asserted-by":"crossref","unstructured":"Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, and Morelli A (2004b) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 14:1444-1456.","DOI":"10.1053\/j.gastro.2004.08.001"},{"key":"10.1124\/jpet.105.085597_bib5","doi-asserted-by":"crossref","unstructured":"Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, et al. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-693.","DOI":"10.1016\/0092-8674(95)90530-8"},{"key":"10.1124\/jpet.105.085597_bib6","doi-asserted-by":"crossref","unstructured":"Friedman SL (2003) Liver fibrosis\u2014from bench to bedside. J Hepatol 38 (Suppl 1): S38-S53.","DOI":"10.1016\/S0168-8278(02)00429-4"},{"key":"10.1124\/jpet.105.085597_bib7","doi-asserted-by":"crossref","unstructured":"Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, and Casini A (2000) Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology 31:101-108.","DOI":"10.1002\/hep.510310117"},{"key":"10.1124\/jpet.105.085597_bib8","doi-asserted-by":"crossref","unstructured":"Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, and Casini A (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122:1924-1940.","DOI":"10.1053\/gast.2002.33666"},{"key":"10.1124\/jpet.105.085597_bib9","doi-asserted-by":"crossref","unstructured":"Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1 and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517-526.","DOI":"10.1016\/S1097-2765(00)00051-4"},{"key":"10.1124\/jpet.105.085597_bib10","doi-asserted-by":"crossref","unstructured":"Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, and Tsukamoto H (2004) Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279:11392-11401.","DOI":"10.1074\/jbc.M310284200"},{"key":"10.1124\/jpet.105.085597_bib11","doi-asserted-by":"crossref","unstructured":"Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, et al. (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124:184-201.","DOI":"10.1053\/gast.2003.50015"},{"key":"10.1124\/jpet.105.085597_bib12","doi-asserted-by":"crossref","unstructured":"Ip E, Farrell G, Hall P, Robertson G, and Leclercq I (2004) Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39:1286-1296.","DOI":"10.1002\/hep.20170"},{"key":"10.1124\/jpet.105.085597_bib13","doi-asserted-by":"crossref","unstructured":"Jarvinen HY (2004) Thiazolidinediones. N Engl J Med 351:1106-1117.","DOI":"10.1056\/NEJMra041001"},{"key":"10.1124\/jpet.105.085597_bib14","doi-asserted-by":"crossref","unstructured":"Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, and Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell 83:813-819.","DOI":"10.1016\/0092-8674(95)90194-9"},{"key":"10.1124\/jpet.105.085597_bib15","doi-asserted-by":"crossref","unstructured":"Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, and Sato N (2002) Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291:55-61.","DOI":"10.1006\/bbrc.2002.6385"},{"key":"10.1124\/jpet.105.085597_bib16","doi-asserted-by":"crossref","unstructured":"Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650.","DOI":"10.1021\/bi0159581"},{"key":"10.1124\/jpet.105.085597_bib17","doi-asserted-by":"crossref","unstructured":"Lopez-De Leon A and Rojkind M (1985) A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33:737-743.","DOI":"10.1177\/33.8.2410480"},{"key":"10.1124\/jpet.105.085597_bib18","doi-asserted-by":"crossref","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, and Shan B (1999) Identification of a nuclear receptor for bile acids. Science (Wash DC) 284:1362-1365.","DOI":"10.1126\/science.284.5418.1362"},{"key":"10.1124\/jpet.105.085597_bib19","doi-asserted-by":"crossref","unstructured":"Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43:2971-2974.","DOI":"10.1021\/jm0002127"},{"key":"10.1124\/jpet.105.085597_bib20","doi-asserted-by":"crossref","unstructured":"Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, et al. (2000) Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119:466-478.","DOI":"10.1053\/gast.2000.9365"},{"key":"10.1124\/jpet.105.085597_bib21","doi-asserted-by":"crossref","unstructured":"Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, and Gonzalez FJ (2003) Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Investig 111:737-747.","DOI":"10.1172\/JCI17223"},{"key":"10.1124\/jpet.105.085597_bib22","doi-asserted-by":"crossref","unstructured":"Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, Willson TM, Khorasanizadeh S, and Rastinejad F (2003) Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 11:1093-1100.","DOI":"10.1016\/S1097-2765(03)00112-6"},{"key":"10.1124\/jpet.105.085597_bib23","doi-asserted-by":"crossref","unstructured":"Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, and Tsukamoto H (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275:35715-35722.","DOI":"10.1074\/jbc.M006577200"},{"key":"10.1124\/jpet.105.085597_bib24","doi-asserted-by":"crossref","unstructured":"Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. (2003) American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948.","DOI":"10.1161\/01.CIR.0000103683.99399.7E"},{"key":"10.1124\/jpet.105.085597_bib25","doi-asserted-by":"crossref","unstructured":"Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, and Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017.","DOI":"10.1002\/hep.1840380427"},{"key":"10.1124\/jpet.105.085597_bib26","doi-asserted-by":"crossref","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science (Wash DC) 284:1365-1368.","DOI":"10.1126\/science.284.5418.1365"},{"key":"10.1124\/jpet.105.085597_bib27","doi-asserted-by":"crossref","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, and Willson TM (2002) 6-\u03b1-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45:3569-3572.","DOI":"10.1021\/jm025529g"},{"key":"10.1124\/jpet.105.085597_bib28","doi-asserted-by":"crossref","unstructured":"Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, and Staels B (2003) Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 17:259-272.","DOI":"10.1210\/me.2002-0120"},{"key":"10.1124\/jpet.105.085597_bib29","doi-asserted-by":"crossref","unstructured":"Shi Y, Hon M, and Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99:2613-2618.","DOI":"10.1073\/pnas.052707099"},{"key":"10.1124\/jpet.105.085597_bib30","doi-asserted-by":"crossref","unstructured":"Tsukamoto H (2002) Hepatic stellate cells as a target for TZD: can we treat liver fibrosis and type II diabetes at the same time? Hepatology 36:1011-1013.","DOI":"10.1002\/hep.510360430"},{"key":"10.1124\/jpet.105.085597_bib31","doi-asserted-by":"crossref","unstructured":"Wang H, Chen J, Hollister K, Sowers LC, and Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol Cell 3:543-553.","DOI":"10.1016\/S1097-2765(00)80348-2"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524322281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524322281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.085597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:34:49Z","timestamp":1739982889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524322281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0022356524322281"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.085597","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor \u03b3 Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.085597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}